Phase II

A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

• EudraCT number: 2016-004288-37
• ClinicalTrials.gov Identifier: NCT03039790
• Sponsor protocol number: NOR-213
• Phase: II
• Population age: adults, elderly
• Gender: male, female
• Starting year @CEV: 2017

Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders

• EudraCT number:2016-002720-91
• Sponsor protocol number: HBnr02
• Phase: II
• Population age: adults
• Gender: male, female
• Starting year @CEV: 2017

A study to evaluate the reactogenicity, safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines - inactivated (SUIVs) (GSK3816302A) in healthy adults aged 18 to 39 years

• EudraCT number:2017-001584-20
• Sponsor protocol number: 207543
• Centre code: Flu-D-Suiv-001
• Phase: II
• Population age: adults (18 to 39y)
• Gender: male, female
• Starting year @CEV: 2017

Safety and reactogenicity study of GlaxoSmithKline (GSK) Biologicals' investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A) in healthy women

• EudraCT number: 2015-005742-58
• ClinicalTrials.gov Identifier: NCT02753413
• Sponsor protocol number: 204813
• Centre code: RSV-F-024
• Phase: II
• Population age: adults (18 to 45y, non-pregnant)
• Gender: female
• Starting year @CEV: 2016

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

• EudraCT number: 2013-003111-22
• ClinicalTrials.gov Identifier: NCT02270944
• Sponsor protocol number: V98_21
• Centre code: GBS_V98_21
• Phase: II
• Population age: adults (18 to 40y)
• Gender: female
• Starting year @CEV: 2015

Phase II study of HPV vaccine in HPV infected women with normal cytology/ASCUS/LSIL

• EudraCT number:2013-003358-25
• ClinicalTrials.gov Identifier: NCT01957878
• Sponsor protocol number: PC10VAC02
• Centre code: 
• Phase: II
• Population age: adults (25 to 50y)
• Gender: female
• Starting year @CEV: 2013

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

• EudraCT number: 2013-001419-64
• ClinicalTrials.gov Identifier: NCT02038907
• Sponsor protocol number: Nor-107
• Centre code: 
• Phase: II
• Population age: adults (18 to 64y)
• Gender: male, female
• Starting year @CEV: 2013

A Phase 2, open-label, single-center, extension study to evaluate the booster response induced by Vi-CRM197 after priming with either Vi-CRM197 or Typherix administered in adult subjects in H01_04TP study

• EudraCT number: 2011-001448-31
• Sponsor protocol number: H01_01E1TP (=EXT H01_01TP)
• Centre code:
• Phase: II
• Population age: adults (18 to 40y)
• Gender: male,female
• Starting year @CEV: 2011